Role of immune-checkpoint inhibitors in lung cancer | Zendy

Prantesh Jain | Zendy; Chhavi Jain | Zendy; Vamsidhar Velcheti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of immune-checkpoint inhibitors in lung cancer

Author(s) -

Prantesh Jain,

Chhavi Jain,

Vamsidhar Velcheti

Publication year - 2018

Publication title -

therapeutic advances in respiratory disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.022

H-Index - 37

eISSN - 1753-4666

pISSN - 1753-4658

DOI - 10.1177/1753465817750075

Subject(s) - medicine , lung cancer , immunotherapy , immune system , pd l1 , cancer , immune checkpoint , cytotoxic t cell , immunology , oncology , biology , biochemistry , in vitro

Immune checkpoint inhibitors, mainly drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) pathways, represent a remarkable advance in lung cancer treatment. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are approved for the treatment of patients with non-small-cell lung cancer, with impressive clinical activity and durable responses in some patients. This review will summarize the mechanism of action of these drugs, the clinical development of these agents and the current role of these agents in the management of patients with lung cancer. In addition, the review will discuss the role of predictive biomarkers for optimal patient selection for immunotherapy and management of autoimmune side effects of these agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research